# Pharmaceutical Economics and Policy

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/pharmaceutical-economics-and-policy/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers explores the economics of pharmaceutical research and development, focusing on topics such as drug development costs, generic drugs, pharmaceutical innovation, medicine prices, patent expiry, healthcare policies, market size, availability of medicines, and generic substitution. |
| Domain | Social Sciences |
| Field | Economics, Econometrics and Finance |
| OpenAlex ID | t11792 |
| Works | 173 |

## Topic papers all

Showing 15 of 173.

- [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS](https://scholariq.org/papers/2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in/)
- [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS](https://scholariq.org/papers/2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-5/)
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS](https://scholariq.org/papers/2017-esc-focused-update-on-dual-antiplatelet-therapy-in-coronary-artery-disease/)
- [Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force](https://scholariq.org/papers/consolidated-health-economic-evaluation-reporting-standards-cheers-explanation/)
- [Data Resource Profile: The Danish National Prescription Registry](https://scholariq.org/papers/data-resource-profile-the-danish-national-prescription-registry/)
- [Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes](https://scholariq.org/papers/early-intensive-vs-a-delayed-conservative-simvastatin-strategy-in-patients-with/)
- [An Introduction to Markov Modelling for Economic Evaluation](https://scholariq.org/papers/an-introduction-to-markov-modelling-for-economic-evaluation/)
- [Delivering affordable cancer care in high-income countries](https://scholariq.org/papers/delivering-affordable-cancer-care-in-high-income-countries/)
- [Essential medicines for universal health coverage](https://scholariq.org/papers/essential-medicines-for-universal-health-coverage/)
- [Key principles for the improved conduct of health technology assessments for resource allocation decisions](https://scholariq.org/papers/key-principles-for-the-improved-conduct-of-health-technology-assessments-for/)
- [Drug development in Alzheimer’s disease: the path to 2025](https://scholariq.org/papers/drug-development-in-alzheimer-s-disease-the-path-to-2025/)
- [Withdrawal of cerivastatin from the world market](https://scholariq.org/papers/withdrawal-of-cerivastatin-from-the-world-market/)
- [Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence](https://scholariq.org/papers/medicines-adherence-involving-patients-in-decisions-about-prescribed-medicines/)
- [Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions](https://scholariq.org/papers/of-principles-and-pens-attitudes-and-practices-of-medicine-housestaff-toward/)
- [National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013](https://scholariq.org/papers/national-trends-in-statin-use-and-expenditures-in-the-us-adult-population-from/)

## Topic primary papers

Showing 15 of 32.

- [Essential medicines for universal health coverage](https://scholariq.org/papers/essential-medicines-for-universal-health-coverage/)
- [Short and long term impacts of COVID-19 on the pharmaceutical sector](https://scholariq.org/papers/short-and-long-term-impacts-of-covid-19-on-the-pharmaceutical-sector/)
- [Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data](https://scholariq.org/papers/availability-and-affordability-of-blood-pressure-lowering-medicines-and-the/)
- [The selection and use of essential medicines.](https://scholariq.org/papers/the-selection-and-use-of-essential-medicines/)
- [Introduction to drug utilization research](https://scholariq.org/papers/introduction-to-drug-utilization-research-2/)
- [Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes](https://scholariq.org/papers/compulsory-generic-switching-of-antiepileptic-drugs-high-switchback-rates-to/)
- [Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers](https://scholariq.org/papers/relative-efficacy-of-drugs-an-emerging-issue-between-regulatory-agencies-and/)
- [Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets](https://scholariq.org/papers/barriers-for-access-to-new-medicines-searching-for-the-balance-between-rising/)
- [Barriers to accessing essential medicines for kidney disease in low- and lower middle–income countries\|](https://scholariq.org/papers/barriers-to-accessing-essential-medicines-for-kidney-disease-in-low-and-lower/)
- [Drug shortages in developed countries—reasons, therapeutic consequences, and handling](https://scholariq.org/papers/drug-shortages-in-developed-countries-reasons-therapeutic-consequences-and/)
- [Factors affecting the uptake of new medicines in secondary care a literature review](https://scholariq.org/papers/factors-affecting-the-uptake-of-new-medicines-in-secondary-care-a-literature/)
- [Consumers' preference and willingness to pay for pharmacist counselling for non-prescription medicines](https://scholariq.org/papers/consumers-preference-and-willingness-to-pay-for-pharmacist-counselling-for-non/)
- [Drivers of Start-Up Delays in Global Randomized Clinical Trials](https://scholariq.org/papers/drivers-of-start-up-delays-in-global-randomized-clinical-trials/)
- [Pharmaceutical regulation in Europe and its impact on corporate R&D](https://scholariq.org/papers/pharmaceutical-regulation-in-europe-and-its-impact-on-corporate-r-and-amp-d/)
- [Accessing medicines for non-communicable diseases: Patients and health care workers’ experiences at public and private health facilities in Uganda](https://scholariq.org/papers/accessing-medicines-for-non-communicable-diseases-patients-and-health-care/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.